- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Phase 3 Data Show STELARA® Induced Clinical Response And Remission In The Treatment Of Patients With Moderate To Severe Crohn’s Disease
Efficacy and Safety Results from First STELARA® Phase 3 Induction Study (UNITI-2)
IMBRUVICA® (ibrutinib) Supplemental New Drug Application for Treatment-naïve Chronic Lymphocytic Leukemia Submitted to the U.S. FDA
Submission seeking potential fifth indication based on data from the Phase 3 RESONATE™-2 (PCYC-1115) trial
Johnson & Johnson Announces BARDA Funding Award to Accelerate Ebola Vaccine Program
Prime-boost vaccine regimen in development at the Janssen Pharmaceutical Companies currently in Phase I and II clinical studies in Europe, U.S. and Africa
U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma
If approved, daratumumab will offer a new option for double refractory, heavily pre-treated patients
Data Published in The New England Journal of Medicine Show Single-Agent Daratumumab Demonstrated a 36 Percent Overall Response Rate and Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients
Study results also showed 65 percent of responding patients remained in remission at 12 months
Janssen Submits European Extension Marketing Authorisation Application for Paliperidone Palmitate Once-Every-Three-Months Formulation
First long-acting treatment to be administered four times a year for the treatment of schizophrenia in adults
Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir
Filing Supported by Data from the Phase 3 OPTIMIST-1 and -2 Clinical Trials Evaluating OLYSIO® Combination Therapy in Hepatitis C Patients with and without Cirrhosis
Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma
Oral presentation (abstract 10503) featured at the Annual Meeting of the American Society of Clinical Oncology
New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer
Janssen Expands EXPLORER Cardiovascular Research Program to Include New, Multi-Trial, Prospective Research Program Aimed at Generating New Evidence in Treating and Preventing Cancer-Associated Blood Clots